Financial Data and Key Metrics Changes - Total global net sales in Q4 reached $218.6 million, a 3% increase supported by strong performances in Bone Growth Therapies and U.S. limb reconstruction segments [13] - Pro forma non-GAAP Adjusted EBITDA was $29.2 million, or 13.4% of net sales, with year-over-year margin expansion of approximately 230 basis points [15] - Free cash flow for Q4 was exceptionally strong at $16.8 million, demonstrating the strength and scalability of the business model [15] Business Line Data and Key Metrics Changes - Bone Growth Therapies (BGT) net sales were $68.3 million, up 7%, significantly outperforming the market [14] - U.S. Limb Reconstruction sales were $38 million in Q4, driven by 8% U.S. growth [14] - Global spine fixation Q4 net sales grew 10% for the year and in Q4, with U.S. spine fixation net sales growing 6% for the year and 5% for the quarter [4][5] Market Data and Key Metrics Changes - U.S. Limb Reconstruction grew 8% in Q4 and 16% for the full year, driven by successful product launches [7] - The BGT business delivered strong sequential fourth quarter growth, reaching 7%, more than double the market rate [8] - The company expects to return to double-digit growth in the second half of 2026 for U.S. Limb Reconstruction as portfolio refinements take hold [14] Company Strategy and Development Direction - The company has rebranded its orthopedics business as Limb Reconstruction, focusing on high-value clinical categories with an estimated $2.6 billion market opportunity [6] - The full market release of the VIRATA Spinal Fixation System is anticipated in the second half of 2026, expected to enhance surgical efficiency and serve as a growth catalyst [6] - The company is recalibrating its three-year financial targets to fully capture the anticipated benefits of its spine commercial channel optimization, extending the timeline to 2028 [10][22] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about entering 2026 with strong momentum and a solid foundation for growth, driven by a focused distributor network and innovation pipeline [11][25] - The company is committed to disciplined execution and targeted capital deployment to create sustainable long-term shareholder value [24][27] - Management highlighted the importance of ongoing product launches and enhancements across all business segments to drive sustained momentum [26] Other Important Information - The company expects full-year net sales of $850 million-$860 million for 2026, representing implied pro forma constant currency year-over-year growth of approximately 5.5% [17] - Adjusted gross margins for the full year 2026 are expected to be approximately 72.5% [18] - The company anticipates $45 million-$50 million in capital expenditures for the year [22] Q&A Session Summary Question: Clarification on CMS impact on BGT - Management clarified that the CMS change will have about a 1% impact in Q1 specific to BGT revenue only [32] Question: Long-range plan and margin improvement - Management explained that the extended timeline reflects the need for a stronger foundation and focus on market execution, with ongoing efforts to improve gross margins and cash generation [34][37] Question: 2026 revenue guidance specifics - Management expects above-market growth for BGT and limb reconstruction, with a return to double-digit growth in the second half of 2026 for limb reconstruction [42] Question: 7D placements and biologics portfolio - Management reported a 30% increase in 7D placements in 2025 and emphasized a renewed focus on advancing the biologics portfolio [51][52] Question: Tariff impact and legal settlements - Management indicated an expected $1 million-$2 million impact from tariffs in 2026 and confirmed that an accrual for a legal settlement was taken in Q3 [57][62]

Financial Data and Key Metrics Changes - MPLX reported adjusted EBITDA of $1.8 billion for the third quarter, reflecting a 3% increase year-over-year [15] - Year-to-date adjusted EBITDA reached $5.2 billion, showing a 4% growth compared to the same period last year [5] - Distributable cash flows amounted to $1.5 billion, supporting a return of $1.1 billion to unit holders [5][15] - The company increased its quarterly distribution by 12.5% for the second consecutive year, marking a total annualized base distribution growth of over 50% in the past four years [4][17] Business Line Data and Key Metrics Changes - In the crude oil and products logistics segment, adjusted EBITDA increased by $43 million compared to Q3 2024, driven by higher rates despite flat pipeline volumes and a 3% decline in terminal volumes [13] - The natural gas and NGL services segment saw adjusted EBITDA rise by $9 million year-over-year, with gathered volumes increasing by 3% primarily due to production growth in the Utica [14] - Processing volumes in the Utica increased by 24% year-over-year, while Marcellus processing utilization was at 95% for the quarter [15] Market Data and Key Metrics Changes - MPLX's investments are primarily focused on natural gas and NGL services, with over 90% of total investments allocated to these segments this year [10] - The company is advancing its strategic growth objectives in the Permian Basin, with significant expansions planned for its processing and treating capabilities [8][10] Company Strategy and Development Direction - MPLX aims for mid-single-digit adjusted EBITDA growth anchored in the Marcellus and Permian basins, supported by strategic acquisitions and capital deployment [5][10] - The company is optimizing its competitive position through acquisitions, including full ownership of the Bangle NGL Pipeline System and a Delaware Basin sour gas treating business [6][8] - MPLX is focused on expanding gathering infrastructure and enhancing butane blending at terminals to maximize asset utilization [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in sustaining mid-single-digit adjusted EBITDA growth, with expectations for stronger growth in 2026 compared to 2025 [22][24] - The company anticipates that adjusted EBITDA growth will not be linear, with a focus on throughput growth from existing and new assets [17] - Management highlighted the importance of strategic partnerships and operational excellence in driving cash flow growth and delivering capital returns to unit holders [18] Other Important Information - MPLX maintains a solid balance sheet with leverage below its comfort level of four times, entering the quarter with a cash balance of $1.8 billion [16] - The company is progressing on schedule and on budget for its Gulf Coast Fractionation facility and LPG export terminal, expected to enter service in 2028 [9] Q&A Session Summary Question: EBITDA growth outlook - Management indicated that growth from 2025 to 2026 is expected to be stronger than from 2024 to 2025, supported by recent acquisitions and projects coming online [22][23] Question: Power LOI and opportunity set - Management discussed the importance of the LOI with MPC, emphasizing the potential for in-basin demand and lower-cost reliable power for producer customers [26] Question: Permian sour gas opportunity - Management confirmed that no additional AGI wells are needed to run the sour gas asset at full capacity, with a $500 million incremental capital investment planned [32] Question: Data center opportunities - Management is evaluating additional letters of intent for data center opportunities, with a focus on supporting producer customers [34] Question: In-basin demand growth - Management highlighted growth in the Marcellus and Utica regions, with expectations for new greenfield pipelines to support demand [50] Question: Distribution growth policy - Management sees a path for 12.5% distribution growth for the next couple of years, with evaluations ongoing beyond that period [65] Question: Impact of crude oil prices on logistics segment - Management noted strong demand and throughput in the logistics segment, supported by partnerships with Marathon Petroleum [71][72]

Financial Data and Key Metrics Changes - The company reported a revenue decline of 3% to $428.2 million, with organic revenue growth of 5% for the quarter [13] - Adjusted EBITDA was $105 million, with an adjusted EBITDA margin of 24.8%, up 80 basis points compared to the first quarter [13] - Adjusted net income was $27.6 million or $0.46 per share, down from $0.59 in the same quarter last year [15][16] - Unlevered free cash flow generated was $54 million, reflecting a 51% conversion of adjusted EBITDA [15] Business Line Data and Key Metrics Changes - Merchant Solutions volume increased by 9% to $35.7 billion, resulting in organic revenue growth of 6% [18] - Digital Wallet revenue was $201.2 million, an increase of 3% on an organic basis [19] - eCash solutions revenue grew by 37% year to date, although the contribution was relatively small at $22 million in the first half [9] Market Data and Key Metrics Changes - E-commerce growth exceeded 30% in the second quarter, with double-digit growth in Europe for the first time in years [11] - The company saw a 20% year-to-date increase in enterprise-level deals and annual contract value bookings [5] Company Strategy and Development Direction - The company aims to drive 10% to 12% annual revenue contribution from products released in the last three years [10] - Continued focus on expanding partnerships, such as with Fiserv, and enhancing product offerings like the Pargo Efectivo wallet [12][10] - The company is targeting an acceleration of organic growth in the second half of the year, expecting 8% to 10% growth [22] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the full-year outlook, supported by a healthy backlog of signed business and strong customer engagement [5][22] - The company anticipates margin improvement in the second half, driven by growth and operating leverage [24] - Management noted that attrition is tracking less favorably at 12%, but they expect improvements moving forward [22] Other Important Information - The company repurchased $20 million worth of shares during the quarter, continuing to view its shares as undervalued [5] - Total debt at the end of the quarter was $2.6 billion, with net leverage increasing to 5.4 times [21] Q&A Session Summary Question: Can you discuss the partnership expansion with Fiserv? - The Clover Capital will be available through the business wallet, reaching directly to consumers, and initial adoption has been positive [28][31] Question: What are the main drivers for organic acceleration in the second half? - The majority of the back half of the year has already been sold, with good visibility into revenue from existing contracts and new product initiatives [39][41] Question: How is the e-commerce business performing across different verticals? - E-commerce growth is strong, with gaming consistently over 50% growth and mid-teen growth in other verticals [44][45] Question: What is the current status of SMB growth and attrition? - SMB mid production has improved significantly, with a positive growth outlook for the back half of the year [52][56] Question: Can you provide insights on the Pago Effectivo Wallet's traction? - The launch has exceeded expectations, with a significant increase in transactions from existing customers [70][72] Question: How is the competitive landscape in e-commerce? - The e-commerce market is highly competitive, but the company sees significant growth opportunities due to its small market share [84][86]